Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS views and news. Opt-in with us: www.register.msviewsandnews.org


~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================================================


Sunday, March 11, 2018

Fingolimod switch from an injectable linked to improved outcomes in relapsing MS

REPORTING FROM ACTRIMS FORUM 2018
 – People with relapsing multiple sclerosis who switched from an injectable disease-modifying therapy to fingolimod after the randomized phase of the PREFERMS trial experienced improved annualized relapse rates, exposure-adjusted percentage brain volume loss, and satisfaction, compared with study participants who did not switch.
Of the 875 patients with relapsing multiple sclerosis, 254 or 58% of those initially randomized to an injectable disease-modifying therapy (iDMT) switched to fingolimod (Gilenya) during the 12-month study. Participants in the trial were permitted to switch therapy once after at least 3 months, or sooner if warranted for safety or efficacy reasons.
Dr. Samuel F. Hunter, a neurologist at Advanced Neurosciences Institute in Franklin, Tenn.Damian McNamara/Frontline Medical News
Dr. Samuel F. Hunter


“The majority of people switched therapy during the trial, and it was very disproportionate from injectable therapies to fingolimod,” said Samuel F. Hunter, MD, PhD, a neurologist at the Advanced Neurosciences Institute in Franklin, Tenn. 

Of those randomized to fingolimod at baseline, 90% remained on fingolimod; in contrast, only 35% of those who started on an injectable chose to remain on the same therapy. About 75% were on fingolimod therapy by the end of the study, he added.

Continue Reading


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
SUBSCRIBE to our MS Learning Channel on YouTube: www.youtube.com/msviewsandnews
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

No comments: